Evidence map›Paper›PMID 33198188›Full record

ArticleBiomolecules2020

Generation and Application of the Zebrafish

Shuxian Lu, Mengyan Hu, Zhihao Wang, Hongkai Liu, Yao Kou, Zhaojie Lyu, Jing Tian

Open access · goldAbstract read
In one paragraph

Article in Biomolecules, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 39 citations in OpenAlex.

  1. Zebrafish in Cardiovascular Disease Research: from Model to Application.International journal of biological sciences · 2026
    Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Zebrafish Congenital Heart Disease Models: Opportunities and Challenges.International journal of molecular sciences · 2024
    Review
  9. Transcriptome studies of inherited dilated cardiomyopathies.Mammalian genome : official journal of the International Mammalian Genome Society · 2023
    Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. A Novel Missense Variant in Actin Binding Domain ofFrontiers in cardiovascular medicine · 2022
    Article
  17. Article
  18. Screening of Potential Anti-Thrombotic Ingredients fromMolecules (Basel, Switzerland) · 2021
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Shuxian LuKey Laboratory of Resource Biology and Biotechnology in Western China, Ministry of Education, School of Medicine, Northwest University, Xi'an 710069, China.
Mengyan HuKey Laboratory of Resource Biology and Biotechnology in Western China, Ministry of Education, School of Medicine, Northwest University, Xi'an 710069, China.
Zhihao WangKey Laboratory of Resource Biology and Biotechnology in Western China, Ministry of Education, School of Medicine, Northwest University, Xi'an 710069, China.
Hongkai LiuKey Laboratory of Resource Biology and Biotechnology in Western China, Ministry of Education, School of Medicine, Northwest University, Xi'an 710069, China.
Yao KouKey Laboratory of Resource Biology and Biotechnology in Western China, Ministry of Education, School of Medicine, Northwest University, Xi'an 710069, China.
Zhaojie LyuKey Laboratory of Resource Biology and Biotechnology in Western China, Ministry of Education, School of Medicine, Northwest University, Xi'an 710069, China.
Jing TianKey Laboratory of Resource Biology and Biotechnology in Western China, Ministry of Education, School of Medicine, Northwest University, Xi'an 710069, China.ORCID 0000-0001-6912-7673
Ministry of Education of the People's Republic of China · CN

Funding

Opening Foundation of Key Laboratory of Resource Biology and Biotechnology in Western China, Ministry of Education ZSK2018010Shaanxi key industry innovation chain (Group) Foundation in social development field, China 2019ZDLSF02-05
6 · The paper itself

Abstract

Cardiovascular disease (CVD) is the leading cause of global mortality, which has caused a huge burden on the quality of human life. Therefore, experimental animal models of CVD have become essential tools for analyzing the pathogenesis, developing drug screening, and testing potential therapeutic strategies. In recent decades, zebrafish has entered the field of CVD as an important model organism. HEG1, a heart development protein with EGF like domains 1, plays important roles in the development of vertebrate cardiovascular system. Loss of HEG1 will affect the stabilization of vascular endothelial cell connection and eventually lead to dilated cardiomyopathy (DCM). Here, we generated a

Indexed as

Disease Models, AnimalAnimalsBlood CirculationCardiovascular DiseasesFemaleGene Knockout TechniquesHeart RateHumansMaleMembrane GlycoproteinsMutationZebrafishZebrafish Proteinsheg1 protein, zebrafishMembrane GlycoproteinsZebrafish Proteinscardiovascular disease (CVD)CRISPR/Cas9dilated cardiomyopathy (DCM)drug screeningheg1thrombosisTraditional Chinese Medicine (TCM)zebrafish model

Identifiers

PMID33198188
PMCPMC7696531
OpenAlexW3103002232

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.